Jensen, Jesper http://orcid.org/0000-0003-2821-9947
Schou, Morten
Kistorp, Caroline
Faber, Jens
Hansen, Tine W.
Jensen, Magnus T.
Andersen, Henrik U.
Rossing, Peter
Vilsbøll, Tina
Jørgensen, Peter G.
Funding for this research was provided by:
Thermo Fisher Scientific
Article History
Received: 9 July 2020
Accepted: 10 October 2020
First Online: 16 October 2020
Ethics approval and consent to participate
: All participants provided written informed consent and the study was approved by the Danish National Committee on Biomedical Research Ethics (amendment to protocol no. H‐3‐2009‐139).
: Not applicable.
: M.S. reports lecture fees received from Novo Nordisk and Boehringer Ingelheim. M.T.J. has served as consultant, on advisory boards, or invited speaker for Astra Zeneca, Novo Nordisk, Novartis, and General Electric. H.U.A. owns stocks in Novo Nordisk. HUA is on advisory boards for Novo Nordisk, Abbott and Astra Zeneca and has received a lecture fee from Nordic Infucare. P.R. reports grants from and shares in Novo Nordisk, service on advisory boards for Astra Zeneca, Bayer, Boehringer Ingelheim, Gilead, Eli Lilly, Novo Nordisk, Merck, Mundipharma, Astellas, Sanofi Aventis (all fees to his institution) and receipt of lecture fees from Bayer, Astra Zeneca and Eli Lilly (to his institution). T.V. reports grants/personal fees/unrestricted research grants from Novo Nordisk, Boehringer, Sanofi, Eli Lilly, MSD/Merck, BMS, Sun Pharmaceuticals, Mundipharma and Amgen. P.G.J. reports lecture fees from Novo Nordisk and Astra Zeneca. The authors have no other relevant conflicts of interest.